Enzon Pharmaceuticals, Inc. (ENZN)

Enzon Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	0.03	-	0.03	0.7	0.05
Revenue Growth (YoY)	-	-	-96.29%	1248.08%	-74.88%
Gross Profit	0.03	-	0.03	0.7	0.05
Selling, General & Admin	1.35	1.04	1.06	1.17	1.36
Operating Expenses	1.35	1.04	1.06	1.17	1.36
Operating Income	-1.33	-1.04	-1.03	-0.47	-1.31
Interest & Investment Income	2.45	2.26	0.65	0.01	-
Other Non Operating Income (Expenses)	-	-	-	-	0
EBT Excluding Unusual Items	1.13	1.22	-0.39	-0.46	-1.3
Pretax Income	1.13	1.22	-0.39	-0.46	-1.3
Income Tax Expense	0.35	-0.16	-0.2	0.01	0.01
Net Income	0.78	1.37	-0.19	-0.47	-1.31
Preferred Dividends & Other Adjustments	1.28	1.28	1.28	2.02	0.46
Net Income to Common	-0.5	0.1	-1.46	-2.49	-1.77
Net Income Growth	-43.34%	-	-	-	-
Shares Outstanding (Basic)	74	74	74	74	51
Shares Outstanding (Diluted)	74	74	74	74	51
Shares Change (YoY)	-	-	-	45.23%	15.57%
EPS (Basic)	-0.01	0.00	-0.02	-0.03	-0.03
EPS (Diluted)	-0.01	0.00	-0.02	-0.03	-0.03
Gross Margin	100.00%	-	100.00%	100.00%	100.00%
Operating Margin	-5103.85%	-	-3969.23%	-66.90%	-2509.62%
Profit Margin	-1911.54%	-	-5619.23%	-355.49%	-3405.77%
EBIT	-1.33	-1.04	-1.03	-0.47	-1.31
EBIT Margin	-	-	-	-66.90%	-
Effective Tax Rate	30.84%	-	-	-	-
Revenue as Reported	0.03	-	0.03	0.7	0.05

Updated Feb 21, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.